Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.
Innovative companies whose purpose is to design and develop new ways to introduce drugs to the body. These new methods may consist of time-released capsules, differing injection techniques, or enabling certain drugs to be taken orally that may not have been to be taken so before. Their revenue is obtained from selling their technology to pharmaceutical companies or licensing it to manufacturers of prescription drugs.
|
| Totals |
Company |
Industry |
| Sales: |
$181.1 Mil |
$111,855.5 Mil |
| Market Cap: |
$810.3 Mil |
$350,022.1 Mil |
| Analysts Recommendation: |
Strong Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
39.2% |
18.0% |
| Estimated Revenue: |
31.1% |
10.2% |
| Historic Earnings: |
N/A |
97.7% |
| Estimated Earnings: |
N/A |
19.6% |
| Stock Price (1 Year): |
(5.7%) |
35.4% |
| Cash per Share: |
(25.4%) |
(10.8%) |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
33.2 |
16.7 |
| Price-to-Sales: |
4.5 |
N/A |
| Price-to-Book: |
(12.4) |
12.8 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$810.3 Mil |
$23,334.8 Mil |
| Operations |
| Net Margin: |
(37.5%) |
(164.0%) |
| Gross Margin: |
75.2% |
75.3% |
| Return on Equity: |
N/A |
(.7) |
| Return on Assets: |
(.4) |
(.2) |
| Balance Sheet |
| Current Ratio: |
1.4 |
2.3 |
| Quick Ratio: |
1.1 |
2.1 |
| Cash Ratio: |
.7 |
1.5 |
| Debt-to-Equity: |
N/A |
4.5 |
| Interest Coverage: |
.1 |
.0 |
| Technicals |
| Relative-Strength Index: |
42.1 |
N/A |
|
|
|
